AstraZeneca expanded its COVID-19 antibody portfolio on Tuesday with a $157 million licensing deal for experimental therapies developed by newly launched biotech company RQ Bio.

4gi.tv
AstraZeneca expanded its COVID-19 antibody portfolio on Tuesday with a $157 million licensing deal for experimental therapies developed by newly launched biotech company RQ Bio.